Synageva BioPharma — Trimeris — Merger or Acquisition (July 2011)
19 slides from Synageva BioPharma's merger presentation, Jul 27, 2011
Slide 1: Filed by Trimeris, Inc. Pursuant to Rule 425
Filed by Trimeris, Inc. Pursuant to Rule 425 under the Securities Act of 1933 (the “Securities Act”) and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 (the “Exchange Act”) Securities Act File Number: 333-175512 Subject Company: Trimeris, Inc. Exchange Act File Number
Slide 2: Trimeris and Synageva: A Value Creating Transaction
Trimeris and Synageva A Value Creating Transaction July 2011
Slide 3: Forward Looking Statements / Additional Information
Forward Looking Statements / Additional Information Forward Looking Statements Certain statements in this communication regarding the proposed merger, conditions to and anticipated completion of the proposed merger, the expected ownership of the combined company and the combined company’s board of d
Slide 4: Overview
Overview Significant potential for value creation inherent in combined Trimeris-Synageva Trimeris Board conducted an extensive and thorough exploration of strategic alternatives Trimeris Board evaluated liquidation scenario and determined it did not maximize value for stockholders
Slide 5: Transaction Overview
Transaction Overview Structure • Reverse stock-for-stock merger • Intended to qualify as a tax-free reorganization • Pro forma ownership: 25% Trimeris; 75% Synageva Post-Closing • Company to be named Synageva BioPharma Corp., headquartered in Boston, MA • Sanj Patel (Synageva CEO) will serve as Pres
Slide 6: Significant Upside Potential Inherent in Combined Trimeris-Synageva
Significant Upside Potential Inherent in Combined Trimeris-Synageva Innovative approaches for rare diseases with high unmet medical need Clinical stage rare disease asset Lead product in clinic with multiple patients dosed and strong pipeline of programs Several orphan therapeutics in development Fu
Slide 7: Attractive Rare Disease Space
Attractive Rare Disease Space Rare disease space offers attractive opportunity due to: Patients with significant unmet medical needs and a lack of effective marketed therapies Small clinical trials –accelerated and less expensive path to commercialization Reduced clinical risk –early clinical data a
Slide 8: Synageva Pipeline of Opportunity
Synageva Pipeline of Opportunity Program SBC-102 SBC-103 SBC-104 SBC-105 SBC-106 (rhLAL) (rhNAGLU) Recombinant Recombinant Enzyme Enzyme Extra Cellular Therapeutic Lysosomal Acid a-N-acetyl- Replacement Replacement Protein Lipase glucosaminidase Therapy Therapy LAL Severe MPS IIIB/ Sanfilippo B Seve
Slide 9: SBC-102: Clinical and Regulatory Milestones
SBC-102: Clinical and Regulatory Milestones Lead program SBC-102: enzyme replacement therapy for Lysosomal Acid Lipase (LAL) • Offers unique therapy to treat LAL Deficiency • Currently no approved treatments for disease IND (Investigational New Drug) filed on schedule and cleared within 30 days EU C
Slide 10: SBC-102: Patient Data - Compassionate Use
SBC-102: Patient Data -Compassionate Use An infant with LAL Deficiency has received treatment with SBC-102 on a compassionate use basis • Presented with anemia, increasingly abnormal liver function tests, and growth failure prior to treatment • Child has received 13+ infusions with no complications
Slide 11: Trimeris Background
Trimeris Background Commercial stage company with $47.3 million in cash (as of 3/31/11) • In 2007, Trimeris began to pare down operations, eliminate development activity and has reduced headcount to three • $4.9 million payment received as part of Rochesettlement in May 2011 Declining financial perf
Slide 12: Extensive and Thorough Board Process
Extensive and Thorough Board Process 2006: Board began exploring alternatives to maximize stockholder value 2007 – 2008: Held discussions with HealthCor Management, largest Trimeris stockholder; appointed two Healthcor representatives to Trimeris Board August 2008 –August 2009: Approached Roche on m
Slide 13: Extensive and Thorough Board Process (continued)
Extensive and Thorough Board Process (continued) February2011: Board established Special Committee,comprised of independent directors Stephen Davis and Barry Quart • Engaged MTS Health Partners and Paul Hastings Identified 47 Tier A and 95 Tier B companies that could have interest in a combination S
Slide 14: Compelling Valuation of Pro Forma Ownership
Compelling Valuation of Pro Forma Ownership Trimeris Special Committee explored the valuation of a combined Trimeris- Synageva based on multiple conservative scenarios, including: • Cumulativeprobability of success of 20%, 45% and 70% - all below Synageva management’s guidance • Reduction in forecas
Slide 15: Liquidation Analysis
Liquidation Analysis Trimeris Board and Special Committee evaluated a liquidation scenario In a liquidation, Trimeris stockholders estimated to receive near-term cash distribution of ~$48 million, or $2.07/share of Trimeris common stock • $2.07/share in cash represents only ~75% of pre-dealmarket ca
Slide 16: Failure to Complete Synageva Merger Could Negatively Impact Trimeris
Failure to Complete Synageva Merger Could Negatively Impact Trimeris’ Financial Condition and/or Stock Price If Synageva merger is not completed: TrimerisBoard would need to reevaluatestrategicalternatives– a process the Board has undertaken for several years Trimeris and Synageva are expected to in
Slide 17: Board Unanimously Recommends Stockholders Vote FOR Proposed Merger with Synageva
Board Unanimously Recommends Stockholders Vote FOR Proposed Merger with Synageva Significant potential for value creation inherent in combined Trimeris-Synageva Trimeris Board conducted an extensive and thorough exploration of strategic alternatives Trimeris Board evaluated liquidation scenario and
Slide 18: Important Merger Information and Additional Information and Where to Find It
Important Merger Information and Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities of Trimeris or Synageva or the solicitation of any vote or approval. In connection with the proposed merger, Trim
Slide 19: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Statements in this communication regarding the development of Synageva’s product candidates, including SBC-102 and SBC-103, preclinical and clinical results from trials involving Synageva’s product candidates, the predictability of enzyme replacem